Long-Term Protective Effect of Serial Infections with H5N8 Highly Pathogenic Avian Influenza Virus in Wild Ducks.
H5N8
HPAIV
mallards
tufted ducks
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
28 09 2022
28 09 2022
Historique:
pubmed:
14
9
2022
medline:
1
10
2022
entrez:
13
9
2022
Statut:
ppublish
Résumé
Highly pathogenic avian influenza viruses (HPAIVs) of the Goose/Guangdong (Gs/Gd) lineage are an emerging threat to wild birds. In the 2016-2017 H5N8 outbreak, unexplained variability was observed in susceptible species, with some reports of infected birds dying in high numbers and other reports of apparently subclinical infections. This experimental study was devised to test the hypothesis that previous infection with a less-virulent HPAIV (i.e., 2014 H5N8) provides long-term immunity against subsequent infection with a more-virulent HPAIV (i.e., 2016 H5N8). Therefore, two species of wild ducks-the more-susceptible tufted duck (Aythya fuligula) and the more-resistant mallard (Anas platyrhynchos)-were serially inoculated, first with 2014 H5N8 and after 9 months with 2016 H5N8. For both species, a control group of birds was first sham inoculated and after 9 months inoculated with 2016 H5N8. Subsequent infection with the more-virulent 2016 H5N8 caused no clinical signs in tufted ducks that had previously been infected with 2014 H5N8 (
Identifiants
pubmed: 36098512
doi: 10.1128/jvi.01233-22
pmc: PMC9517725
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0123322Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00014
Pays : United States
Références
Emerg Microbes Infect. 2020 Dec;9(1):180-193
pubmed: 31969057
Zoolog Sci. 2019 Dec 9;36(6):490-503
pubmed: 31833320
Epidemiol Infect. 2018 Feb;146(3):306-313
pubmed: 29325601
Clin Vaccine Immunol. 2009 Jun;16(6):824-9
pubmed: 19386796
Vet Med Sci. 2016 Jan 18;2(1):36-46
pubmed: 29067179
EFSA J. 2019 Dec 19;17(12):e05945
pubmed: 32626213
Dev Comp Immunol. 2000 Mar-Apr;24(2-3):269-83
pubmed: 10717293
Emerg Infect Dis. 2017 Dec;23(12):2050-2054
pubmed: 29148372
J Wildl Dis. 2010 Jul;46(3):896-911
pubmed: 20688695
J Vet Sci. 2017 Aug 31;18(S1):269-280
pubmed: 28859267
Philos Trans R Soc Lond B Biol Sci. 2019 Jun 24;374(1775):20180257
pubmed: 31056053
PLoS One. 2010 Jan 28;5(1):e8935
pubmed: 20126617
J Virol. 2016 Oct 14;90(21):9967-9982
pubmed: 27558429
J Virol Methods. 2016 Feb;228:130-4
pubmed: 26645952
Emerg Infect Dis. 2008 Apr;14(4):600-7
pubmed: 18394278
Emerg Microbes Infect. 2021 Dec;10(1):148-151
pubmed: 33400615
PLoS One. 2011 Jan 06;6(1):e15987
pubmed: 21253608
Euro Surveill. 2015 Mar 26;20(12):
pubmed: 25846491
Euro Surveill. 2016 Sep 22;21(38):
pubmed: 27684783
J Wildl Dis. 2020 Jan;56(1):47-57
pubmed: 31556839
J Vet Diagn Invest. 2009 Sep;21(5):579-87
pubmed: 19737752
Emerg Microbes Infect. 2018 Apr 18;7(1):67
pubmed: 29670093
Vet Res. 2020 Sep 14;51(1):117
pubmed: 32928280
EFSA J. 2020 Dec 16;18(12):e06379
pubmed: 33343738
Euro Surveill. 2018 Jan;23(4):
pubmed: 29382414
J Virol. 2015 Nov;89(22):11507-22
pubmed: 26339062
Avian Dis. 2015 Dec;59(4):543-7
pubmed: 26629630
Emerg Microbes Infect. 2021 Dec;10(1):97-108
pubmed: 33350337
Science. 2016 Oct 14;354(6309):213-217
pubmed: 27738169
PLoS Pathog. 2017 Jun 22;13(6):e1006419
pubmed: 28640898
Proc Biol Sci. 2013 Jun 05;280(1763):20130990
pubmed: 23740783
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20814-20825
pubmed: 32769208
Emerg Microbes Infect. 2018 Jul 19;7(1):132
pubmed: 30026505